Head-to-head evidence
AZD1775 vs BMS-986463
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: WEE1 kinase · full Non-Small Cell Lung Cancer pipeline
AZD1775
Developed by AstraZeneca
NCT02087176 · Phase 2 · terminated
Although this study was designed as a randomized, blinded, placebo-controlled trial, it was stopped early by the sponsor, and only a single-arm safety cohort of 32 patients reported results, with no completed comparison against placebo. A single-arm response rate cannot show whether AZD1775 adds benefit over docetaxel alone.
BMS-986463
Developed by Bristol-Myers Squibb
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2028 · NCT06476808 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD1775's landscape · BMS-986463's landscape